DCGI Waives Bridging Trials For Foreign Approved COVID Vaccines

The Drugs Controller General of India on June 2 waived the requirement of foreign companies to conduct ‘post-launch bridging trials’ of COVID vaccines. The announcement came for the vaccines approved by specific countries and the WHO. The drug regulatory body cited ‘huge vaccination requirements in India decision was taken because of. Notably, the bridging trials are conducted to generate data in India-specific context assessing efficacy on Indian participants.